How is oral testosterone undecanoate dosed?
| Product | Capsule strength | Dose on the label (starting dose where the label titrates) |
|---|---|---|
| Jatenzo1 | 158, 198 or 237 mg | 237 mg twice daily with food |
| Tlando3 | 112.5 mg | 225 mg twice daily with food, as two capsules |
| Kyzatrex2 | 50, 100, 150 or 200 mg | 200 mg twice daily with food |
| Restandol Testocaps (Ireland)4 | 40.0 mg | Initial dosage of 120 to 160 mg daily for two to three weeks, then 40 to 120 mg daily by clinical effect |
Capsule strengths and labelled starting doses
The table is set at the top of the page
The products are different formulations, and the labels do not give a conversion between their doses.
How the dose is adjusted
The Jatenzo label sets the range at 158 to 396 mg twice daily, adjusted on serum testosterone drawn 6 hours after the morning dose, at least 7 days after starting or changing.1 Its table keeps the dose unchanged at 425 to 970 ng/dL and steps by capsule strength.1
The Kyzatrex label has the blood check 7 days after starting or adjusting, 3 to 5 hours after the morning dose.2 Its table steps between 100 mg with breakfast only and 400 mg twice daily with meals, with no change at 460 to 971 ng/dL.2 Above a total of 100 mg a day, the same dose is given morning and evening.2 The Tlando label reports its safety data from 225 mg twice daily without titration, in 233 men across two studies.3
Timing, food and route
The Restandol leaflet says the capsules must be taken with a meal and swallowed whole without chewing, and that it is preferable to take half the daily dose in the morning and half in the evening.4 The Jatenzo label gives the route as oral.1 In a 5-way crossover study by Yin and colleagues in 16 hypogonadal men, a single dose of a new self-emulsifying formulation with 300 mg of testosterone equivalents, described as the maximum anticipated human dose per administration, gave average and peak serum testosterone that rose with the meal's fat content, though neither the 50% nor the 20% fat meal showed a significant food effect against the 30% fat meal.5
What the trials used
The phase 3 trials of Jatenzo (Swerdloff), Tlando (SOAR, Miner) and Kyzatrex (Bernstein) started at 237, 225 and 200 mg twice daily and titrated from there.678
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Swerdloff, Jatenzo phase 36 | 237 mg twice daily before breakfast and dinner, titrated | 221 men randomized 3:1 to oral (166) or topical testosterone (Axiron) | 3 to 4 months |
| Miner, SOAR (Tlando)7 | 225 mg twice daily, adjusted by 75 mg per dose at weeks 4 and 8 | 315 patients randomized 2:1 to oral or 1.62% topical testosterone gel | Visits through week 52 |
| Bernstein, single-arm Kyzatrex trial8 | 200 mg twice daily with breakfast and the evening meal, then titrated | 155 participants | 180 days of dosing |
| White, Tlando blood pressure study9 | 225 mg twice daily | 138 men with hypogonadism | 4 months |
| Bouloux, 1-year dose-ranging trial10 | Placebo, or 80, 160 or 240 mg a day in divided doses with meals | 322 men aged 50 or older with symptoms of testosterone deficiency | 1 year |
| Skakkebaek, double-blind crossover trial11 | 160 mg daily by mouth against placebo | A 12-man group of hypogonadal men (six hypergonadotrophic, six hypogonadotrophic) | Not given |
How it is stored
The Jatenzo label says to store at 20 to 25 C and keep the capsules dry, and the Kyzatrex label gives 20 to 25 C in a dry place away from excessive moisture and humidity.12 The Tlando label gives 20 to 25 C with excursions to 15 to 30 C.3 The Restandol leaflet says to store below 30 C, not to refrigerate or freeze, with a 3-year shelf life.4
Frequently asked questions
Does oral testosterone undecanoate need mixing or a syringe?
Every oral product found is a ready-made capsule, so there is no mixing step and no syringe volume.
Is there a dosing protocol for cycles or non-labelled use?
Searches of PubMed, ClinicalTrials.gov and DailyMed returned no label, human trial or cycle protocol for bodybuilding or non-medical use. The Jatenzo label says the drug is indicated for testosterone replacement in adult males with a deficiency or absence of endogenous testosterone.1
What do the labels say about blood pressure?
The Jatenzo and Kyzatrex labels say the capsules can raise blood pressure.12 In the Tlando label's Study 18-001, ambulatory blood pressure was monitored in 138 men, and the 123 with acceptable recordings at baseline and after about 16 weeks had a mean systolic change of +4.3 mmHg.3 In the 155-man Kyzatrex blood pressure study (White), the mean change in systolic pressure was 1.7 mmHg at day 120 and 1.8 mmHg at day 180.12
- Oral testosterone undecanoateHalf-life, trials and doses reported.
- Testosterone estersThe class overview.
- Testosterone replacementHow replacement therapy is set up.
- Testosterone enanthate dosageThe injectable ester.
- Testosterone cypionate dosageThe injectable ester.
- Sustanon injection dosageThe blended injectable.
References
- DailyMed. These highlights do not include all the information needed to use JATENZO ® safely and effectively. See full prescribing information for JATENZO. JATENZO (testosterone undecanoate) capsules, for oral use CIII Initial U.S. Approval: 1953. 2026. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use KYZATREX® safely and effectively. See full prescribing information for KYZATREX®. KYZATREX® (testosterone undecanoate) capsules, for oral use, CIII Initial U.S. approval: 1953. 2026. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use TLANDO ® safely and effectively. See full prescribing information for TLANDO. TLANDO (testosterone undecanoate) capsules, for oral use, CIII Initial U.S. Approval: 1953. 2026. dailymed.nlm.nih.gov
- HPRA. Health Products Regulatory Authority. assets.hpra.ie
- PMC. Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Self-Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal Men. 2012. pmc.ncbi.nlm.nih.gov
- PMC. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. 2020. pmc.ncbi.nlm.nih.gov
- PMC. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. 2024. pmc.ncbi.nlm.nih.gov
- PMC. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. 2024. pmc.ncbi.nlm.nih.gov
- PubMed. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. 2021. pubmed.ncbi.nlm.nih.gov
- PubMed. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. 2013. pubmed.ncbi.nlm.nih.gov
- PubMed. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. 1981. pubmed.ncbi.nlm.nih.gov
- PMC. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. 2021. pmc.ncbi.nlm.nih.gov